July 23rd 2024
AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer.
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Larotrectinib and The Risk of Fracture in TRK Fusion Thyroid Cancer
September 29th 2021Theodore W. Laetsch, MD, an attending physician with the Cancer Center at Children’s hospital of Philadelphia discusses if there is an increased risk of fractures with larotrectinib in patients with TRK fusion positive thyroid cancer.
Read More
BRAF/MEK Inhibitor Combination Shows Promise in Anaplastic Thyroid Cancer
September 28th 2021Principle study investigator Yuliya Mikheeva, MD, PhD, of Saint-Petersburg State University, discussed the combination of dabrafenib and trametinib for the treatment of anaplastic thyroid cancer in an interview with Targeted Oncology.
Read More
Multiple Trials Examined for RET-Targeted Therapies in MTC
September 27th 2021A 58-year-old man presented with a solitary nodule on the neck, occasional shortness of breath, and intermittent excessive fatigue. Twelve months after being treated with systemic therapy, symptoms occurred leading the oncologist to discover metastatic disease.
Read More
The Importance of Patient-Reported Outcomes in The LIBRETTO-001 Trial
September 23rd 2021Lori Wirth, MD, discusses the relevance of patient-reported outcomes from the phase 1/2 LIBRETTO-001 study in of selpercatinib in patients with RET-altered medullary thyroid cancer or advanced thyroid cancer.
Watch
FDA Approves Cabozantinib for RAI-Refractory Locally Advanced or Metastatic DTC
September 20th 2021The FDA has approved cabozantinib for the treatment of patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible.
Read More
FDA Approval Decision Pending on Cabozantinib as a New Treatment Option for RR-DTC
August 11th 2021Progression-free survival was significantly prolonged with cabozantinib as treatment of patients with radioiodine-refractory differentiated thyroid cancer in the phase 3 COSMIC-311 clinical trial, showing potential as a new treatment option and leading to the filing of a application for FDA approval.
Read More
Weill Cornell Medicine Becomes First to Test CAR T Cells in Patients With R/R Thyroid Cancer
August 6th 2021A non-randomized, open-label trial of AIC100, an autologous chimeric antigen receptor T-cell agent for the treatment of relapsed/refractory thyroid cancer, is currently recruiting patients at the Weill Cornell Medical College in New York, under the supervision of Koen van Besien, MD, PhD.
Read More